<DOC>
	<DOCNO>NCT03040089</DOCNO>
	<brief_summary>This prospective , multi-center , split-face , control clinical trial aim investigate efficacy safety picosecond , neodymium-doped yttrium aluminum garnet laser laser therapy patient melasma , compare 2 % hydroquinone cream . The trial perform two Korean institution 45 subject .</brief_summary>
	<brief_title>Efficacy Safety Picosecond , Neodymium-doped Yttrium Aluminum Garnet Laser Therapy Using 1,064 nm 595 nm</brief_title>
	<detailed_description />
	<mesh_term>Melanosis</mesh_term>
	<mesh_term>Hydroquinone</mesh_term>
	<criteria>Females age 19 74 Has Fitzpatrick Skin Type IIIV Diagnosed moderate severe ( GSS â‰§ 2 ) melasma lesion Agreed prohibition use local/systemic corticosteroid retinoids local/systemic lightening medication , willing abide instruction Agreed use facial skin care product clinical trial period ( include followup period ) , willing abide instruction Agreed daily use SPF 50 sunblock face clinical trial period ( include followup period ) , willing abide instruction Agreed face photograph ( In case fertile woman ) Tested negative pregnancy test agree use birth control contraceptives clinical trial period Oral contraceptive forbid may influence result clinical study . Agreed undergo procedure face participation clinical trial Voluntarily agree sign write consent form willing follow instruction study protocol Participated another medical device medication clinical trial last 3 month , plan participate another trial trial Received cosmetic treatment laser , light therapy , surgery facial area last 6 month , history filler treatment use collagen , hyaluronic acid , material Diagnosed incurable melisma Has history allergic reaction local anesthesia Has history malignant tumor face Has skin lesion cut , wound , injury face Pregnant breastfeeding Has infection , dermatitis , rash face Currently diagnose uncontrolled diabetes cardiac disorder resistant hypertension Currently diagnose anticoagulant disease take anticoagulant Has history keloid scarring , hypertrophic scarring , abnormal would heal Has history immunodeficiency intake immunosuppressant Has history leukoplakia , eczema , psoriasis Has history connective tissue disease systemic lupus erythematosus scleroderma Has history convulsive disorder cause light Has history disease irritate heat face ( e.g. , herpes simplex herpes zoster ) Has history radiotherapy anticancer chemotherapy face Has history hormonal therapy last 3 month ( e.g. , estrogen , progesterone , oral contraceptive ) Has history use lighten medication ( hydroquinone , tranexamic acid ) , isotretinoid ( retinoid ) , lightsensitive medication , steroid last 6 month Has excessive facial tan Other subject assess inadequate clinical trial investigator</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>